title: Molecular genetics of familial hypercholesterolemia in Israel.
abstract: Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by a multitude of low density lipoprotein receptor (LDL-R) mutations. The purpose of the current investigation was to define the spectrum of mutations causing FH in Israel and determine their relative distribution among diverse origin groups. A total of 193 FH families were recruited in Israel, 54 of them through the MED PED (Make Early Diagnosis Prevent Early Death) FH program. Molecular analysis of the LDL-R using single-strand conformation polymorphism (SSCP) or denaturing gradient gel electrophoresis (DGGE) or both has been completed in 95 index cases. This analysis resulted in the identification of 15 LDL receptor mutations, including 7 novel mutations (del 197, C308G, R385W, splice junction mutation of intron 14, del 328, del 502-505, stop 10, del 165), that were present in 49 index cases (52%). The 15 mutations are mapped to three known functional domains of the receptor (7 in the LDL-binding region, 7 in the epidermal growth factor precursor homology region and 1 in the membrane-spanning region). Screening for the identified mutations in the remaining 98 index cases enabled the molecular diagnosis of 31 additional cases. It is therefore concluded that 80 out of 193 index cases (41%) harbor 1 of the 15 mutations described here. Three mutations-del197 (FH-Lithuania), D147H (FH-Sephardic), and stop660 (Lebanese allele)-were found in a total of 66 index cases (34%); these may be regarded as founder mutations in the three respective origin groups. In conclusion, in Israel molecular heterogeneity at the LDL receptor gene locus reflects the ethnic distribution of its origin groups. The results of the present investigation provide valuable diagnostic tools for a subset of the Israeli patients with FH who are at high risk for atherosclerosis and its complications.
authors.affiliation: Division of Medicine, Center for Research Prevention and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Reshef
authors.forename: H
authors.initials: H
authors.lastname: Nissen
authors.forename: L
authors.initials: L
authors.lastname: Triger
authors.forename: T S
authors.initials: TS
authors.lastname: Hensen
authors.forename: O
authors.initials: O
authors.lastname: Eliav
authors.forename: D
authors.initials: D
authors.lastname: Schurr
authors.forename: R
authors.initials: R
authors.lastname: Safadi
authors.forename: M
authors.initials: M
authors.lastname: Gare
authors.forename: E
authors.initials: E
authors.lastname: Leitersdorf
mesh_terms: D018912:Arabs / Q000235:genetics; D015139:Blotting, Southern; D004252:DNA Mutational Analysis; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000235:genetics*; D007557:Israel; D007585:Jews / Q000235:genetics; D009154:Mutation; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011973:Receptors, LDL / Q000235:genetics
chemical_list: D011973:Receptors, LDL